
Frantz EyeCare reports 98% of Light Adjustable Lens patients achieved refractive accuracy within ±0.50 D of target, exceeding published national cataract surgery benchmarks.
The FDA has approved Akorn Inc.'s abbreviated new drug application for neomycin and polymyxin B sulfates, and bacitracin zinc ophthalmic ointment USP, a generic therapeutic equivalent to Monarch Pharmaceuticals' Neosporin ophthalmic ointment.




